Perpetual Medicines Completes $8 Million Seed Round To Advance Integrated Computational Design-synthesis Platform For Peptide Drug Discovery

Perpetual Medicines has completed a $8 million seed financing round led by Chengwei Capital, representing a significant step forward in the advancement of their integrated computational design and synthesis platform for peptide drug development. The company's strategy makes use of recent advances in computer modeling, artificial intelligence (AI), deep learning, and machine learning to investigate the huge and unexplored chemical space for peptide-based drug development.

Appointments and the Leadership Team:

Kerry L. Blanchard, MD, PhD, has joined Perpetual Medicines as Co-founder, Chairman, and CEO; Ved Srivastava, PhD, has joined as Chief Technology Officer; and Xiang Ye, PhD, has joined as Chief Scientific Officer. The team has over 120 years of combined experience in drug discovery, with a focus on peptide therapies.

Platform for Computational Drug Discovery:

The computer platform of Perpetual Medicines enables virtual iteration over millions of peptide sequences. It combines experimental data integration with physics-based simulations to anticipate binding and drug-like properties in order to uncover and optimize prospective therapeutic candidates. This novel approach has the potential to speed the peptide drug development process, minimize expenses, and improve drug candidate quality.

Market Potential and Opportunity:

The company intends to profit on the rapidly expanding peptide therapies market, which is expected to approach $140 billion annually by 2030. Peptides, which fall between small molecule pharmaceuticals and therapeutic antibodies, provide distinct advantages in preventing protein interactions both inside and outside of cells. Perpetual Medicines intends to study new target classes and address previously unsolvable pathobiology with access to a larger chemical space.

Read More - https://bit.ly/3TbZtxn